haloperidol has been researched along with oseltamivir in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Eyanagi, R; Imoto, M; Kuroki, H; Nishimura, S; Shimeno, H; Soeda, S; Toda, A; Uchiyama, H; Watanabe, S | 1 |
| Hayashi, Y; Ishikawa, H; Suzuki, T | 1 |
| Hayashi, Y; Ishikawa, H; Orita, H; Suzuki, T; Uchimaru, T | 1 |
| Hayashi, Y; Ogasawara, S | 1 |
1 review(s) available for haloperidol and oseltamivir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for haloperidol and oseltamivir
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The stimulatory effects of caffeine with oseltamivir (Tamiflu) on light-dark behavior and open-field behavior in mice.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Antiviral Agents; Caffeine; Darkness; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Exploratory Behavior; Flumazenil; GABA Modulators; GABA-A Receptor Antagonists; Haloperidol; Male; Mice; Motor Activity; Neurotransmitter Agents; Oseltamivir; Pyrimidines; Random Allocation; Triazoles; Xanthines | 2010 |
High-yielding synthesis of the anti-influenza neuramidase inhibitor (-)-oseltamivir by three "one-pot" operations.
Topics: Animals; Antiviral Agents; Catalysis; Ethers; Humans; Influenza, Human; Oseltamivir; Proline; Stereoisomerism | 2009 |
High-yielding synthesis of the anti-influenza neuraminidase inhibitor (-)-oseltamivir by two "one-pot" sequences.
Topics: Antiviral Agents; Catalysis; Combinatorial Chemistry Techniques; Ethers; Humans; Molecular Structure; Neuraminidase; Oseltamivir; Proline; Stereoisomerism | 2010 |
Time Economical Total Synthesis of (-)-Oseltamivir.
Topics: Antiviral Agents; Catalysis; Efficiency; Ethers; Formates; Oseltamivir; Proline; Stereoisomerism; Thiourea | 2016 |